Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference36 articles.
1. De Nicola L, Minutolo R, Chiodini P, on behalf of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006;69:538–45.
2. McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78:215–23.
3. European Medicines Agency [EMA]. Biosimilar medicines. London: EMA; 2013.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp&mid=WC0b01ac0580281bf0
. Accessed 16 Jun 2017.
4. Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34:609–16.
5. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Pollina Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G. How much are biosimilars used in clinicalpractice? A retrospective italian population-based study of erythropoiesis-stimulating agents in the years 2009–2013. BioDrugs. 2015;29(4):275–84.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献